Cantor Fitzgerald Issues Positive Outlook for YMAB Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Cantor Fitzgerald increased their FY2024 EPS estimates for shares of Y-mAbs Therapeutics in a report released on Monday, November 11th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings per share of ($0.66) for the year, up from their previous forecast of ($0.67). Cantor Fitzgerald has a “Overweight” rating and a $20.00 price objective on the stock. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.64) per share.

YMAB has been the subject of a number of other research reports. BMO Capital Markets lowered their target price on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a research report on Friday. Wedbush reissued an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $26.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Finally, Morgan Stanley cut their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Y-mAbs Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.14.

Y-mAbs Therapeutics Stock Down 3.9 %

Shares of NASDAQ:YMAB opened at $11.14 on Thursday. Y-mAbs Therapeutics has a fifty-two week low of $5.04 and a fifty-two week high of $20.90. The firm’s 50 day moving average price is $13.98 and its 200 day moving average price is $13.09. The stock has a market cap of $498.96 million, a price-to-earnings ratio of -20.63 and a beta of 0.68.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its earnings results on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The company had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period in the previous year, the firm earned ($0.18) earnings per share.

Institutional Investors Weigh In On Y-mAbs Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. lifted its stake in shares of Y-mAbs Therapeutics by 39.9% during the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after buying an additional 1,056 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Y-mAbs Therapeutics by 8.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock valued at $345,000 after purchasing an additional 1,657 shares during the period. Caxton Associates LP purchased a new position in Y-mAbs Therapeutics during the first quarter worth about $306,000. Boston Partners purchased a new position in Y-mAbs Therapeutics during the first quarter worth about $556,000. Finally, Bank of New York Mellon Corp boosted its stake in Y-mAbs Therapeutics by 8.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock worth $1,461,000 after buying an additional 8,974 shares during the last quarter. 70.85% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 65,000 shares of the stock in a transaction on Friday, September 13th. The stock was sold at an average price of $13.47, for a total value of $875,550.00. Following the completion of the transaction, the insider now owns 97,681 shares in the company, valued at approximately $1,315,763.07. This represents a 39.96 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Joris Wilms sold 5,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $14.69, for a total transaction of $73,450.00. Following the completion of the sale, the chief operating officer now owns 30,600 shares of the company’s stock, valued at $449,514. This trade represents a 14.04 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 100,000 shares of company stock valued at $1,338,100. 22.50% of the stock is owned by company insiders.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.